Patents by Inventor Afjal Hussain Miah

Afjal Hussain Miah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugates comprising RIPK2 inhibitors
    Patent number: 10781205
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 22, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
  • Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
    Patent number: 10730862
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 4, 2020
    Assignees: Yale University, Glaxosmithkline Intellectual Property Development, Cambridge Enterprise Limited University of Cambridge
    Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Denton Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
  • NOVEL COMPOUNDS
    Publication number: 20190382381
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 19, 2019
    Inventors: Linda N. CASILLAS, John David HARLING, Afjal Hussain MIAH, Mark David RACKHAM, Ian Edward David SMITH
  • Compounds
    Patent number: 10435391
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 8, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Linda N. Casillas, John David Harling, Afjal Hussain Miah, Mark David Rackham, Ian Edward David Smith
  • Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
    Publication number: 20190127359
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: December 18, 2018
    Publication date: May 2, 2019
    Inventors: CRAIG M. CREWS, DENNIS BUCKLEY, ALESSIO CIULLI, WILLIAM L. JORGENSEN, PETER C. GAREISS, INGE VAN MOLLE, JEFFREY GUSTAFSON, HYUN-SEOP TAE, JULIEN MICHEL, DENTON WADE HOYER, ANKE G. ROTH, JOHN DAVID HARLING, IAN EDWARD DAVID SMITH, AFJAL HUSSAIN MIAH, SEBASTIEN ANDRE CAMPOS, JOELLE LE
  • CONJUGATES COMPRISING RIPK2 INHIBITORS
    Publication number: 20190119271
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Application
    Filed: April 18, 2017
    Publication date: April 25, 2019
    Inventors: Linda N. CASILLAS, John David HARLING, Afjal Hussain MIAH, Mark David RACKHAM, Ian Edward David Smith
  • Benzothiophene derivatives as estrogen receptor inhibitors
    Patent number: 9988376
    Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: June 5, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Sebastien Andre Campos, John David Harling, Afjal Hussain Miah, Ian Edward David Smith
  • NOVEL COMPOUNDS
    Publication number: 20180134688
    Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
    Type: Application
    Filed: April 20, 2016
    Publication date: May 17, 2018
    Inventors: Linda N. CASILLAS, John David HARLING, Afjal Hussain MIAH, Mark David RACKHAM, Ian Edward David SMITH
  • BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS
    Publication number: 20160368911
    Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation.
    Type: Application
    Filed: July 1, 2014
    Publication date: December 22, 2016
    Applicant: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Sebastien Andre CAMPOS, John David HARLING, Afjal Hussain MIAH, Ian Edward, David SMITH
  • Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
    Publication number: 20140356322
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Dentin Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le